Moreover, EZH2 may serve not only as a biomarker for predicting prognosis, targeting EZH2 in HNSCC not only holds promise as a personalized therapeutic approach for patients but also requires further exploration to completely grasp the clinical implications it may have. This evidence concerns the gene EZH2 and head and neck squamous cell carcinoma.